Streetbeat News

Stock Prices

CAT

Caterpillar shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:26 am

VVX

V2X (NYSE:VVX) reported Q2 2024 earnings of $0.83 per share, significantly beating the analyst estimate of $0.19. Sales also surpassed expectations, reaching $1.072 billion. Despite the earnings beat, EPS decreased by 24.55% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:26 am

UBER

Uber Technologies shares are trading higher after the company reported better-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:26 am

ELEV

Elevation Oncology announced that its existing cash, cash equivalents, and marketable securities totaling $110.8 million as of June 30, 2024, are expected to be sufficient to fund its current operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:25 am

ELEV

Elevation Oncology reported a Q2 2024 GAAP EPS of $(0.18), which beats the estimated $(0.22).

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:24 am

TDG

TransDigm has raised its FY24 outlook, with sales now expected to be between $7.87 billion and $7.93 billion, up from the previous range of $7.68 billion to $7.80 billion. The adjusted EPS is also increased to a range of $32.62 to $33.42, compared to the prior range of $31.75 to $33.09. These figures are in line with or slightly above analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:19 am

BAX

Baxter International Inc. has updated its 2024 adjusted EPS forecast to a range of $2.93-$3.01, which is higher than its previous guidance of $2.88-$2.98 and the consensus estimate of $2.91.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:19 am

HGTY

Hagerty has raised its FY24 revenue guidance from $1.150B-$1.170B to $1.160B-$1.180B, which is still below the $1.69B estimate.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:18 am

BLMN

Bloomin' Brands has lowered its FY24 outlook, now expecting EPS of $2.10-$2.30 compared to the previous estimate of $2.41 and prior view of $2.51-$2.66. The company also projects U.S. comparable restaurant sales to be down 1% to flat, versus the prior view of flat to +2%.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:18 am

ELEV

Elevation Oncology has reported initial data from the dose escalation portion of its ongoing Phase 1 clinical trial of EO-3021. The trial showed a 42.8% confirmed objective response rate (ORR) in a subset of patients with Claudin 18.2-enriched gastric and GEJ cancer. The company observed minimal MMAE-associated toxicities and plans to advance into monotherapy dose expansion and combination cohorts, with additional data expected in the first half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:18 am